Tirzepatide
GLP-1/GIP agonist
A dual GIP and GLP-1 agonist with strong evidence for glucose control and substantial weight reduction.
Research chemical vendors can't legally label products with the real name, so Tirzepatide often appears under coded SKUs. If you're shopping and see any of these, it's the same compound:
- 2T
- GLP-2
- GLP2
- Branch-2T· Branch Peptides
- Ion-2T· Ion Peptides
- Tirz
- Mounjaro (Rx)
- Zepbound (Rx)
Codes shown are for identification only. Always verify third-party COAs before purchase.
Tirzepatide is a once-weekly dual GIP and GLP-1 receptor agonist. It is sold as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and other labeled indications. The two incretin pathways work together on appetite, glucose-dependent insulin release, glucagon signaling, and metabolic regulation. In obesity trials, higher-dose groups achieved average weight reductions around 20%, though individual response and tolerability vary.
The labeled starting dose is a treatment-initiation dose, not a maintenance target. Nausea, diarrhea, constipation, vomiting, and reduced appetite are common during escalation. Product labeling includes contraindications and warnings that should be reviewed with a clinician.
- Type 2 diabetes treatment with substantial A1C reduction
- Chronic weight management with a higher average trial response than semaglutide in head-to-head research
- Once-weekly dosing and a labeled step-up schedule designed around tolerability
- An approved option for people discussing a dual agonist with their clinician
Educational only · Not a vendor claim
Combines GIP and GLP-1 receptor activity. Together they influence appetite, glucose-dependent insulin secretion, glucagon response, and metabolic handling of nutrients.
- Substantial A1C reduction in type 2 diabetes trials
- Average weight reduction around 20% at higher studied doses in a major obesity trial
- Improvements in waist circumference and several cardiometabolic markers
- Once-weekly administration
- Reduced hunger and food preoccupation
- Progressive weight change during escalation and maintenance
- Blood glucose may improve quickly in diabetes
- GI symptoms often cluster around dose increases
- Approved dual-agonist therapy
- Stronger average weight-loss response than semaglutide in head-to-head obesity research
- Robust diabetes and obesity trial program
- Standardized labeled products
- GI tolerability still limits some users
- Stopping commonly leads to weight regain
- Can contribute to lean-mass loss without adequate nutrition and resistance training
- Coverage and cost vary
- Nausea, diarrhea, or constipation
- Vomiting, reflux, or abdominal discomfort
- Reduced appetite and dehydration
- Gallbladder problems and injection-site reactions
- Serious persistent abdominal pain needs urgent evaluation
Educational summary · Not medical advice · Discuss with a qualified clinician
Typical timeline
General pattern for the Fat Loss category. Individual response varies.
- Week 1Titrate up slowly. Expect appetite drop, mild nausea, and possible constipation with GLP-1s. Hydrate and lean on fiber.
- Weeks 2–4Steady weight trend down (0.5–1.5 lb/week is healthy). Prioritize protein (~1 g/lb lean mass) to protect muscle.
- Weeks 4–8Body composition visibly shifts. Add resistance training if you haven't — muscle preservation is the whole game.
- Weeks 8+Re-evaluate dose. Consider a maintenance drop or a scheduled break to reset receptor sensitivity.
Pairs well with
Common combinations experienced users run alongside Tirzepatide. Always add one peptide at a time so you can attribute effects and side effects.
Read the safety guide before stacking.
The reconstitution math
- 1Reconstitute the 10 mg vial with 2 mL of bacteriostatic water. Tilt — don't shake.
- 2Concentration becomes 5,000 mcg/mL (5 mg/mL).
- 3For a 2 mg dose, draw 0.400 mL — that's 40 units on a 1 mL insulin syringe.
- 4One vial gives you approximately 5 doses.
Reminder: 100 units on an insulin syringe = 1 mL. Always start at half the listed dose for the first week and rotate injection sites between arms, legs, abdomen, and glutes.
Sign in to keep a private log of your doses and notes for Tirzepatide.
Use code ANYPEPTIDES15 for 15% off your order.
Discount may end or change without notice.